Compare ARK Genomic Revolution ETF (ARKG) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs iShares MSCI South Korea ETF — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while iShares MSCI South Korea ETF trades at $169.51. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | EWY | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $43.57 | $219.20 |
52-Week Low | $23.09 | $70.65 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
EWY, the iShares MSCI South Korea ETF, is trading at $183.52, down 0.62% amid bearish technical signals. The ETF faces headwinds from South Korea's Kospi Index entering a local bear market, declining 21% from its YTD high. Heavy concentration in Samsung and SK Hynix exposes EWY to AI chip volatility, with recent earnings pressure from weak EV demand at LG Energy Solution. Technical indicators show a bearish moving average crossover and ADX signaling strong downtrend momentum.
Despite the pullback, EWY remains a leveraged play on AI semiconductor demand through its top holdings. The outlook hinges on sustained AI memory demand and Samsung's performance, with potential upside from SK Hynix's planned U.S. listing. Key risks include single-stock concentration, global tech volatility, and Korea's delayed developed-market status. The current bearish trend suggests cautious entry points near support at $179-180 may offer better risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
